02.01.2020 | Brief Report
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis
Erschienen in: Clinical Rheumatology | Ausgabe 3/2020
Einloggen, um Zugang zu erhaltenAbstract
Key Points • A subset of patients with JIA uveitis either remain unresponsive or experience loss of efficacy • JAK inhibitors may provide a new valuable treatment option in JIA patients with uveitis • The safety profile was good with no occurrence of systemic side effects |